ADREVIEW Drug Patent Profile
✉ Email this page to a colleague
When do Adreview patents expire, and what generic alternatives are available?
Adreview is a drug marketed by Ge Healthcare and is included in one NDA.
The generic ingredient in ADREVIEW is iobenguane sulfate i-123. One supplier is listed for this compound. Additional details are available on the iobenguane sulfate i-123 profile page.
Summary for ADREVIEW
US Patents: | 0 |
Applicants: | 1 |
NDAs: | 1 |
Finished Product Suppliers / Packagers: | 1 |
Raw Ingredient (Bulk) Api Vendors: | 4 |
Clinical Trials: | 7 |
Patent Applications: | 2 |
What excipients (inactive ingredients) are in ADREVIEW? | ADREVIEW excipients list |
DailyMed Link: | ADREVIEW at DailyMed |
Recent Clinical Trials for ADREVIEW
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
Mayo Clinic | Phase 4 |
ABX CRO | Phase 3 |
TFS Trial Form Support | Phase 3 |
US Patents and Regulatory Information for ADREVIEW
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Ge Healthcare | ADREVIEW | iobenguane sulfate i-123 | SOLUTION;INTRAVENOUS | 022290-001 | Sep 19, 2008 | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |